Home Newsfeeds Cowen & Co. Upgrades Carpenter Tech to Outperform, Announces $45 Price Target

Cowen & Co. Upgrades Carpenter Tech to Outperform, Announces $45 Price Target

Cowen & Co. analyst Gautam Khanna upgrades Carpenter Tech (NYSE:CRS) from Market Perform to Outperform and announces $45 price target.

byBenzinga Newsdesk

September 12, 2022

1 minute read

Cowen & Co. analyst Gautam Khanna upgrades Carpenter Tech (NYSE:CRS) from Market Perform to Outperform and announces $45 price target.

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $73 Price Target

By Benzinga Newsdesk

March 1, 7:19 AM

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $73 price target.

CLDX

EXCLUSIVE: Ocean Biomedical’s Co-Founder Jack Elias To Receive US Patent For Lung Fibrosis Therapeutics

By Vandana Singh

April 20, 7:30 AM

Ocean Biomedical Inc's (NASDAQ: OCEA) co-founder Jack Elias, received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for his U.S. patent application covering a therapeutic molecule for pulmonary fibrosis.

OCEA

News
Tech

Tesla CEO Elon Musk Slams Report Of Robot ‘Attacking’ Employee At Giga Texas: ‘Truely Shameful’

By Anan Ashraf

December 28, 2:11 AM

Tesla Inc (NASDAQ:TSLA) CEO Elon Musk, on Wednesday, expressed dismay at a report of an alleged robot ‘attack’…

TSLA

News

Reported Late Thursday March 9, BlueRiver Acquisition Corp. To Transfer Listing To NYSE American; Anticipates The Transfer To The NYSE American To Occur On Or About March 14, 2023

By Happy Mohamed

March 10, 1:42 AM

BlueRiver Acquisition Corp. (NYSE:BLUA) ("BlueRiver"), announced today that it intends to transfer its listing from the New York Stock Exchange (the "NYSE") to the NYSE American LLC (the "NYSE

BLUA

Cowen & Co. Upgrades Carpenter Tech to Outperform, Announces $45 Price Target

Related Posts

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $73 Price Target

EXCLUSIVE: Ocean Biomedical’s Co-Founder Jack Elias To Receive US Patent For Lung Fibrosis Therapeutics

Tesla CEO Elon Musk Slams Report Of Robot ‘Attacking’ Employee At Giga Texas: ‘Truely Shameful’

Reported Late Thursday March 9, BlueRiver Acquisition Corp. To Transfer Listing To NYSE American; Anticipates The Transfer To The NYSE American To Occur On Or About March 14, 2023